Trial Profile

A clinical study of GQ-303

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GQ 303 (Primary)
Indications Osteoarthritis
Focus Adverse reactions

Most Recent Events

26 Nov 2019 New trial record
12 Nov 2019 According to an Flexion Therapeutics media release, the company's gene therapy candidate FX201 receives IND clearance by FDA triggering milestone payment from Flexion to GeneQuine Biotherapeutics. This will facilitate the transition of GeneQuine's independent lead program GQ-303 from preclinical to clinical stage expected in 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com